# MET exon 14 skipping mutation

Source: https://onco.cc/biomarkers/met-ex14/  
OnCo record `met-ex14` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MET exon 14 skipping is a splice-site change that lets the MET receptor escape degradation and keep signalling. It is found in 3 to 4 percent of lung cancers and is treated with capmatinib or tepotinib.

## Summary

Mutations at the exon 14 splice acceptor or donor sites, or in the Y1003 juxtamembrane region, cause the exon to be skipped, removing the CBL binding site. They are detected by DNA sequencing (with splice-site coverage) or, more sensitively, RNA sequencing of tissue or plasma. Capmatinib (Tabrecta, 2020) is labelled for metastatic NSCLC with a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test, and tepotinib (Tepmetko, 2021) for NSCLC harbouring MET exon 14 skipping alterations; FoundationOne CDx and Liquid CDx are the companion diagnostics for both.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: METex14; MET exon 14 skipping; MET ex14; METΔex14; MET exon 14 alteration; MET splice site mutation
- Tags: biomarker; met

## Sources

- TABRECTA prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=455892c3-d144-4ba8-9ab4-79cabff9876d
- TEPMETKO prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80a0f1b9-071a-47f5-9e67-32d638a669dc

## Connected records

- biomarkers: [c-Met protein overexpression (IHC 3+ in >= 50% of tumour cells)](https://onco.cc/biomarkers/met-overexpression/), [MET amplification (gene copy number)](https://onco.cc/biomarkers/met-amplification-readout/)
- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Capmatinib](https://onco.cc/drugs/capmatinib/), [Capmatinib & tepotinib](https://onco.cc/drugs/capmatinib-tepotinib/), [FoundationOne CDx / Liquid CDx](https://onco.cc/drugs/foundationone-cdx/), [Tepotinib](https://onco.cc/drugs/tepotinib/)
- terms: [MET exon 14 skipping mutation](https://onco.cc/terms/met-exon-14-skipping/), [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/)
- targets: [MET](https://onco.cc/targets/met/)

---
JSON: https://onco.cc/api/v1/entities/met-ex14.json